

Oracle Life Sciences Argus

E2B(R3) Best Practices



Release 2026.1.01

G52180-01

March 2026

The Oracle logo, consisting of the word "ORACLE" in white, uppercase, sans-serif font, centered within a solid red square.

ORACLE®

Oracle Life Sciences Argus E2B(R3) Best Practices, Release 2026.1.01

G52180-01

Copyright © 2022, 2026, Oracle and/or its affiliates.

This software and related documentation are provided under a license agreement containing restrictions on use and disclosure and are protected by intellectual property laws. Except as expressly permitted in your license agreement or allowed by law, you may not use, copy, reproduce, translate, broadcast, modify, license, transmit, distribute, exhibit, perform, publish, or display any part, in any form, or by any means. Reverse engineering, disassembly, or decompilation of this software, unless required by law for interoperability, is prohibited.

The information contained herein is subject to change without notice and is not warranted to be error-free. If you find any errors, please report them to us in writing.

If this is software, software documentation, data (as defined in the Federal Acquisition Regulation), or related documentation that is delivered to the U.S. Government or anyone licensing it on behalf of the U.S. Government, then the following notice is applicable:

U.S. GOVERNMENT END USERS: Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs) and Oracle computer documentation or other Oracle data delivered to or accessed by U.S. Government end users are "commercial computer software," "commercial computer software documentation," or "limited rights data" pursuant to the applicable Federal Acquisition Regulation and agency-specific supplemental regulations. As such, the use, reproduction, duplication, release, display, disclosure, modification, preparation of derivative works, and/or adaptation of i) Oracle programs (including any operating system, integrated software, any programs embedded, installed, or activated on delivered hardware, and modifications of such programs), ii) Oracle computer documentation and/or iii) other Oracle data, is subject to the rights and limitations specified in the license contained in the applicable contract. The terms governing the U.S. Government's use of Oracle cloud services are defined by the applicable contract for such services. No other rights are granted to the U.S. Government.

This software or hardware is developed for general use in a variety of information management applications. It is not developed or intended for use in any inherently dangerous applications, including applications that may create a risk of personal injury. If you use this software or hardware in dangerous applications, then you shall be responsible to take all appropriate fail-safe, backup, redundancy, and other measures to ensure its safe use. Oracle Corporation and its affiliates disclaim any liability for any damages caused by use of this software or hardware in dangerous applications.

Oracle®, Java, MySQL, and NetSuite are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Intel and Intel Inside are trademarks or registered trademarks of Intel Corporation. All SPARC trademarks are used under license and are trademarks or registered trademarks of SPARC International, Inc. AMD, Epyc, and the AMD logo are trademarks or registered trademarks of Advanced Micro Devices. UNIX is a registered trademark of The Open Group.

This software or hardware and documentation may provide access to or information about content, products, and services from third parties. Oracle Corporation and its affiliates are not responsible for and expressly disclaim all warranties of any kind with respect to third-party content, products, and services unless otherwise set forth in an applicable agreement between you and Oracle. Oracle Corporation and its affiliates will not be responsible for any loss, costs, or damages incurred due to your access to or use of third-party content, products, or services, except as set forth in an applicable agreement between you and Oracle.

Contents

Preface

About this content	i
Related resources	i

1 Revision history

2 Introduction

3 Set up reporting destinations to send E2B(R3) report

Configure the EDI and Report tabs for EMA and PMDA	2
Configure the EDI and Report tab for FDA	2
Configure Attachments	3
Configure Folders	4
Configure Studies for FDA IND or Pre-ANDA reporting	4
Configure expedited rules	5
Supported Scenarios for FAERS E2B(R3)	6

4 Configure parameters for E2B(R3) Reports and Acknowledgment

5 Customize Mappings and Validations

Preface

This preface contains the following sections:

- [About this content](#)
- [Related resources](#)

About this content

Except where noted, information in this guide applies to both Oracle Argus Safety and Oracle Safety One Argus environments.

Related resources

For information about Oracle Argus patches, see [My Oracle Support](#).

All documentation and other supporting materials are available on the [Oracle Help Center](#).

1

Revision history

Argus version	Description
8.4	First release
8.4.1	Updated the Customize Mappings and Validations section.
8.4.2	Updated the Set up reporting destinations to send E2B(R3) report and Introduction sections with FDA-specific recommendations.
8.4.3	Updated the Set up reporting destinations to send E2B(R3) report section to include the Apply EMA Special Rules parameter and added the Configure Folders section.
8.4.4	Updated the following sections: <ul style="list-style-type: none">• Configure Attachments• Configure Folders• Configure Studies for FDA IND or Pre-ANDA reporting• Configure expedited rules• Configure parameters for E2B(R3) Reports and Acknowledgment
2026.1.01	Updated the Configure the EDI and Report tabs for EMA and PMDA and Configure expedited rules sections. In addition, the Supported Scenarios for FAERS E2B(R3) section has been added.

2

Introduction

This document describes best practices and recommendations to configure the EMA, FDA, and PMDA agencies and common profile switches for the E2B(R3) reports.

3

Set up reporting destinations to send E2B(R3) report

You need to set up reporting destinations when sending E2B(R3) reports. Provide the following information in the **Agency Information** tab and **Local Company Contact** tab:

Agency Information tab

Enter name and email address information of the agency as applicable.

Local Company Contact tab

Enter name and address information of the local company contact that is responsible for ICSR submission. The following data can be updated for ICSR submission other than the mandatory fields shown in UI:

- Sender Type
- Department
- Contact Name information
 - Title
 - First Name
 - Last Name
 - Address
 - City
 - State
 - Postal Code
 - Country
 - Phone
 - Fax
 - Email Address

For more information, see:

- [Configure the EDI and Report tabs for EMA and PMDA](#)
- [Configure the EDI and Report tab for FDA](#)
- [Configure Attachments](#)
- [Configure Folders](#)
- [Configure Studies for FDA IND or Pre-ANDA reporting](#)
- [Configure expedited rules](#)
- [Supported Scenarios for FAERS E2B\(R3\)](#)

This table summarizes the FDA-supported reporting scenarios for submitting Individual Case Safety Reports (ICSRs) to FAERS by using the E2B(R3) standard.

Configure the EDI and Report tabs for EMA and PMDA

The following table lists and describes the fields on the EDI and Report tabs to be set up for the EMA and PMDA profiles:

Agency Identifier	EVCTM or EVPM	PMDA
Secondary Agency/Department Identifier	Not applicable	Not applicable
File type	XML	XML
Company identifier	As applicable	As applicable
Message Profile	ICH-ICSR V3.0 MESSAGE TEMPLATE - EMA	ICH-ICSR V3.0 MESSAGE TEMPLATE - PMDA
ACK Profile	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - EMA	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE - PMDA
Suppress ACK transmission	Marked	Unchecked (Default)
Transmit ICSR Attachments	Marked	Marked
Attachment Classification	As applicable	As applicable
Allowed attachment file size (in MB)	15 MB	15 MB
Allowed report size (in MB)	100 MB	AS1: 10 MB AS2: 50 MB
Incoming folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
Outgoing folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
ICSR Attachment Outgoing Folder	Not required	Not required
File Name	As required, for example: EVVPM_#####.xml	As required, for example: PMDA_#####.xml
Method	E2B EDI gateway	E2B EDI gateway
Apply EMA Masking Rules	Marked	Not Marked

Note

You can check the **Apply EMA Masking Rules** checkbox to apply EMA masking rules when you submit ICSRs to EudraVigilance (EVPM and EVCTM).

Configure the EDI and Report tab for FDA

The following table lists and describes the fields on the EDI and Report tabs to be set up for the FDA profile:

Field	IND report	Pre-ANDA report	Post Marketed report
Agency Identifier	ZZFDA_PREMKT	ZZFDA_PREMKT	ZZFDA

Field	IND report	Pre-ANDA report	Post Marketed report
Secondary Agency/ Department Identifier	CDER_IND or CBER_IND	CDER_IND_EXEMPT_B A_BE	CDER
File type	XML	XML	XML
Company identifier	As applicable	As applicable	As applicable
Message Profile	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS	ICH-ICSR V3.0 MESSAGE TEMPLATE – FAERS
ACK Profile	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS	ICH-ICSR V3.0 ACKNOWLEDGMENT TEMPLATE – FAERS
Suppress ACK transmission	Unchecked (Default)	Unchecked (Default)	Unchecked (Default)
Transmit ICSR Attachments	Marked	Marked	Marked
Attachment Classification	As applicable	As applicable	As applicable
Allowed attachment file size (in MB)	15 MB	15 MB	15 MB
Allowed report size (in MB)	100 MB	AS1: 10 MB AS2: 50 MB	100 MB
Incoming folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
Outgoing folder	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter	Refer to the Configure Folders chapter
ICSR Attachment Outgoing Folder	Not required	Not required	Not required
File Name	As required, for example: IND_#####.xml	As required, for example: PREANDA_##### .xml	As required, for example: NDA_#####.xml
Method	E2B EDI gateway	E2B EDI gateway	E2B EDI gateway
Apply EMA Special Rules	Marked	Marked	Marked

Note

You can check the **Apply EMA Special Rules** checkbox to apply EMA special instruction rules for cases that have at least one Reporter's Country that belongs to the European Union.

Configure Attachments

The file attachment types allowed for ICH, EMA, MFDA and NMPA E2B(R3) profiles are configured in **System Configuration > Common Profile Switch > Reporting > E2B**.

The file attachment types allowed for eVAERS and FDA E2B(R3) are configured in **Flexible Re-Categorization Code Lists > codelist name MEDIATYPE** with attributes FDA and FAERS respectively.

Configure Folders

If the common profile switch **Base directory path for gateway folders** is specified, then the Base directory path can be `\\10.100.80.100\Gatewaysharedfolder\`. The In/Out folders then need to be specified with sub folder path such as `EVPM\IN`, `EVPM\OUT`.

The Interchange services creates folders in the format `<Base folder path>\<Abbreviated Enterprise name >\<Sub folder path>`. If the folder name created by the Interchange services is not required when inserting the Abbreviated name of the Enterprise between the base directory path and the sub folder path, then the **Interchange service to exclude Enterprise abbreviated name for folder creation** parameter in the EDI tab of Reporting Destination code list needs to be marked.

If the Common profile Switch **Base directory path for gateway folders** is not specified, then In/Out folders need to be specified with an absolute path such as `\\10.100.80.100\Gatewaysharedfolder\EVPM\IN`. Interchange services creates folders using the folder structure provided in the Sub folder path.

Configure Studies for FDA IND or Pre-ANDA reporting

IND Studies

Make sure to enter the clinical reference for IND studies, including the primary IND number associated with the study. Optionally, you can also add the cross-reported IND number, if applicable.

Reference Type	Country	Reference Number
CDER-IND or CBER-IND	United States	Select the Primary IND number.
Cross reported IND	United States	Enter the cross reported IND.

Pre-ANDA Studies

Make sure to enter the clinical reference for Pre-ANDA studies and include the primary IND number associated with the study.

Reference Type	Country	Reference Number
Pre-ANDA	United States	Enter the Pre-ANDA number.

Note

Cross-reported IND numbers [FDA C.5.6.r] for IND reports are auto-populated by Interchange based on the product's license configuration. Refer to the FAERS mappings in the E2B R3 mapping document for additional details. Additionally, manually configured INDs in the study will also be transmitted.

Configure expedited rules

Make sure to enter the following information in the reporting rules created for IND, Pre-ANDA and Spontaneous IND Study cases in addition to other reporting criteria that are configured in the expedited rules.

The following rules are based on the ICHICSR/E2B message type and report format. Except for the CDER-30 Day WORLD rule, all rules apply exclusively to the United States.

Rule	Reporting Destination	License Type	Time Frame	Condition
CDER-15 Day	ZZFDA/CDER	Marketed Drug	15	Serious (Event) = Yes
CDER-60 Day	ZZFDA/CDER	Marketed Drug	60	Case Serious = No; Any other condition as per your company's business process
CDER-5 Day	ZZFDA/CDER	Marketed Drug (for Combination Products)	5	Criteria using Advance conditions <ul style="list-style-type: none"> Remedial Action exists Case Classification = Combination Product any other condition as per your company's business process
CDER-30 Day	ZZFDA/CDER	Marketed Drug (for Combination Products)	30	Case Serious = No Criteria using Advance conditions <ul style="list-style-type: none"> Malfunction = Yes Case Classification = Combination Product Any other condition as per your company's business process
CDER-30 Day WORLD	ZZFDA/CDER	Marketed Drug (for Combination Products)	30	Case Serious = No Criteria using Advance conditions: <ul style="list-style-type: none"> Case Classification = Combination Product Malfunction = Yes Product type = Treatment/ Other Drug not administered = Yes Similar Device = Yes
IND - CDER-15 Day IND-CBER-15 Day	ZZFDA_PREM KT/CDER_IND ZZFDA_PREM KT/CBER_IND	Investigational drug	15	Event Serious =Yes and Listedness (Event) = No Study Reference Type=CDER-IND/ CBER-IND Any other condition as per your company's business process
IND - CDER-7 Day IND - CBER-7 Day	ZZFDA_PREM KT/CDER_IND ZZFDA_PREM KT/CBER_IND	Investigational drug	7	Event Serious =Yes and Listedness (Event) = No S/UL/Fatal/LT = Yes Study Reference Type=CDER-IND/ CBER-IND Any other condition as per your company's business process

Rule	Reporting Destination	License Type	Time Frame	Condition
Pre-ANDA	ZZFDA_PREM KT/ CDER_IND_EX EMPT_BA_BE	Investigational drug	15	Event Serious =Yes and Listedness (Event) = No Study Reference Type=Pre-ANDA Any other condition as per your company's business process
IND for Post Marketed Cases	ZZFDA_PREM KT/CDER_IND or CBER_IND	Investigational drug	15 or 7	Event Serious =Yes and Listedness (Event) = No Study Reference Type=Ignore Any other condition as per your company's business process

Transitioning from MedWatch to E2B(R3)

If you are transitioning from MedWatch format to E2B(R3) for IND reporting to FDA, then it is recommended the existing rules used for reporting to FDA by updating the report form to E2B, and configure additional information required as specified above.

When transitioning, the first E2B(R3) report generated from a case in place of the MedWatch report will be displayed as an initial report.

If transitioning from E2B(R2) to E2B(R3), then the follow-up numbering will continue.

If you decide to create a new agency, any case updates are transmitted as an initial report to the new agency.

If you are not transitioning from the MedWatch format to E2B(R3) for FDA reporting, then it is recommended to modify the `Reporting Destination > Message Profile` used for MedWatch reporting to `FDA MEDWATCH 3500A DRUG TEMPLATE`.

If the profile in the agency settings is changed to the `FDA MEDWATCH 3500A DRUG TEMPLATE` or the `E2B(R3) profile ICH-ICSR V3.0 MESSAGE TEMPLATE - FAERS`, then it is not recommended to switch back to the MedWatch paper reporting format.

Supported Scenarios for FAERS E2B(R3)

This table summarizes the FDA-supported reporting scenarios for submitting Individual Case Safety Reports (ICSRs) to FAERS by using the E2B(R3) standard.

Scenario	Batch Receiver Identifier (N.1.4)	Message Receiver Identifier (N.2.r.3)	Type of Report (C.1.3)	Study Type Where Reaction(s) / Event(s) Were Observed (C.5.4)	IND Number where AE Occurred (FDA C.5.5a)	Additional Details
Pre-market report on an IND or IND-Exempt BA/BE study	ZZFDA_P REMKT	CDER_I ND or CBER_I ND or CDER_I ND_EXE MPT_BA _BE	2 (Report from study)	1 (Clinical trials)	<IND Number> or <Pre-ANDA Number>	List cross-referenced INDs in FDA.C.5.6.r

Scenario	Batch Receiver Identifier (N.1.4)	Message Receiver Identifier (N.2.r.3)	Type of Report (C.1.3)	Study Type Where Reaction(s) / Event(s) Were Observed (C.5.4)	IND Number where AE Occurred (FDA C.5.5a)	Additional Details
CDER report from Clinical Case : Solicited reports or reports from Organized Data Collection System	ZZFDA	CDER	2 (Report from study)	2 (Individual patient use) or 3 (Other studies)	Use nullFlavor NA if not available	N/A
Pre-market report with cross-referenced INDs	ZZFDA_P REMKT	CDER_I ND or CBER_I ND	2 (Report from study)	1 (Clinical trials)	<IND Number>	List cross-referenced INDs in FDA.C.5.6.r
Spontaneous IND : Pre-market IND not approved and not marketed in US but is marketed outside of the US, where AE occurred.	ZZFDA_P REMKT	CDER_I ND or CBER_I ND	1 (Spontaneous)	N/A	<IND Number>	N/A
For a post-market study report, submit two reports: IND and NDA/BLA.	Report 1: ZZFDA_P REMKT Report 2: ZZFDA	Report 1: CDER_I ND or CBER_I ND Report 2: CDER	Both: 2 (Report from study)	Both: 1 (Clinical trials)	<IND Number> (for Report 1)	N/A
Post-market safety report	ZZFDA	CDER	1 (Spontaneous)	N/A	(empty)	N/A
Pre-market IND not approved/not marketed inside/outside US, AE outside US.	ZZFDA_P REMKT	CDER_I ND or CBER_I ND	2 (Report from study)	1 (Clinical trials)	<IND Number>	N/A
Pre-market INDs not approved/not marketed inside/outside US, AE outside US.	ZZFDA_P REMKT	CDER_I ND or CBER_I ND	2 (Report from study)	1 (Clinical trials)	<Parent IND Number>	N/A
Pre-market AGGREGATE report	ZZFDA_P REMKT	CDER_I ND or CBER_I ND	2 (Report from study)	1 (Clinical trials)	<IND Number> (parent IND)	Patient = AGGREGATE; Linked Report IDs required

For more information, see the *FAERS E2B(R3) IND Aggregate Report Generation Guidelines* article on MOS (ID:KB868496) and the *ArgusInterchange2025.4.01_E2B (R3) Export Mappings* document.

FAERS IND reporting - CROSSREPORTEDIND[C.5.6.r]

This table summarizes the different system-supported methods for populating the Cross Reported IND (C.5.6.r) field in FAERS IND submissions.

Scenario	Description
Automatic mapping from related licenses: transmit each unique license number as a separate repeating cross-referenced IND element. Duplicate and withdrawn licenses are not transmitted.	License numbers (excluding the value populated in C.5.5a for the case) that belong to the same case study product and associated with other studies as a Clinical Reference Number with Reference Type = CDER_IND / CBER_IND, where: <ul style="list-style-type: none"> Type = INV Country = USA License number with the following logic: For example: Product 1 Contains License1 and License2, Type=INV and Country= USA, Study 1 includes Product 1; License 1 Study 2 includes Product 1; License 2 When FAERS IND report is generated for Study 1, License 1 as INDNUMB[C.5.5.a], License 2 is transmitted as CROSSREPORTEDIND[C.5.6.r].
Direct mapping from Study Configuration: these configured references are transmitted as cross-referenced INDs.	From Study Configuration > Clinical References, where Reference Type = Cross Reported IND and Country = United States.
Direct mapping from Case Form > Additional Information: any INDs provided here are transmitted as cross-referenced IND numbers (unique values only).	From Case Form > Additional Information > Reference > Cross Reported IND
No cross-reported INDs: the element is populated with nullFlavor = NA (Not Applicable).	Applies when none of the above sources provide any cross-reported IND numbers.

4

Configure parameters for E2B(R3) Reports and Acknowledgment

The following switches need to be reviewed and adjusted according to your requirements:

Common profile switch	Description
Default viewing format of the E2B R3 report	Allows you to configure the default view of displaying E2B(R3) in the ICSR viewer. The default value is Decoded view. The available options are XML View or HL7 View.
Default viewing format of the PMDA E2B R3 report (used with Interchange-J)	Allows you to configure the default view of displaying PMDA E2B(R3) in the ICSR viewer. The default value is Decoded view. The options available are: <ul style="list-style-type: none">• XML View• HL7 View• Paper View

Configure parameters for E2B(R3) acknowledgment

The following parameters, located in `Console > Code Lists > Argus > Reporting Destination > EDI`, affect acknowledgment (ACK) and need to be reviewed and adjusted according to your requirements:

Parameter	Description
Local time zone to process Date/Timestamp values of Ack	Allows you to configure the offset to be applied to the following elements in the acknowledgment file if the offset is missing: E2B R3 ACK file - ACK.M.4 messagedater3 PMDA Device ACK file - ACK.6 ACKCREATEDATE

5

Customize Mappings and Validations

Argus Interchange allows you to customize the mappings and validations. For details on how to customize E2B(R3) profiles, refer to the *Oracle Argus Interchange ICSR Extensibility Guide*.

Adherence to conformance rules and validation can be achieved during data entry by creating field validations in Argus Console.

For example, the below general date validations can be configured on the corresponding fields to warn user during data entry to take corrective action.

- Death Date must be greater than equal to Patient Date of Birth
- Parent date of birth must be earlier than date of birth for patient
- Date value in Date of Start of Reaction/Event must be lesser or equal to the Date of Death

For more details on how to configure field validations, refer to the *Oracle Argus Safety Administration Guide > System Configuration > Configuring Field Validations*.